• +1-646-491-9876
    • +91-20-67278686

    Search

    Ischemia Reperfusion Injury - Pipeline Review, H1 2017

    Ischemia Reperfusion Injury - Pipeline Review, H1 2017

    • Report Code ID: RW0001689381
    • Category Healthcare
    • No. of Pages 148
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2017, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

    Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 26 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 4 molecules, respectively.

    Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Ischemia Reperfusion Injury - Overview 7
    Ischemia Reperfusion Injury - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 17
    Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 20
    Amyndas Pharmaceuticals LLC 20
    Angion Biomedica Corp 20
    Biomedica Management Corp (Inactive) 21
    Bolder Biotechnology Inc 21
    Corline Biomedical AB 22
    Curatis Pharma GmbH 22
    Erimos Pharmaceuticals LLC 23
    Hope Pharmaceuticals Inc 23
    Ischemix Inc 24
    Kowa Company Ltd 24
    NovelMed Therapeutics Inc 25
    Omeros Corp 25
    Opsona Therapeutics Ltd 26
    Orexo AB 26
    Pharming Group NV 27
    Prolong Pharmaceuticals LLC 27
    Proteo Inc 28
    Prothix BV 28
    Recordati SpA 29
    SBI Pharmaceuticals Co Ltd 29
    Ischemia Reperfusion Injury - Therapeutics Assessment 30
    Assessment by Target 30
    Assessment by Mechanism of Action 33
    Assessment by Route of Administration 36
    Assessment by Molecule Type 38
    Ischemia Reperfusion Injury - Drug Profiles 40
    AM/AMBP-1 - Drug Profile 40
    aminolevulinic acid hydrochloride - Drug Profile 41
    ANV-6L15 - Drug Profile 42
    AP-39 - Drug Profile 43
    APP-103 - Drug Profile 44
    BB-3 - Drug Profile 45
    BBT-059 - Drug Profile 49
    BMC-011 - Drug Profile 50
    C1 esterase inhibitor (recombinant) - Drug Profile 51
    CMX-2043 - Drug Profile 58
    CRX-526 - Drug Profile 60
    Curaglutide - Drug Profile 61
    Des-Asp Angiotensin 1 - Drug Profile 62
    EP-80317 - Drug Profile 63
    FDY-5301 - Drug Profile 64
    hemin (human) - Drug Profile 65
    KN-93 - Drug Profile 66
    MG-53 - Drug Profile 68
    mirococept - Drug Profile 70
    Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile 71
    Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 72
    Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74
    Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 75
    Neutrolide - Drug Profile 76
    NK-104 NP - Drug Profile 78
    NP-202 - Drug Profile 79
    Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile 80
    OMS-721 - Drug Profile 81
    OPN-305 - Drug Profile 88
    PEG-HCC - Drug Profile 91
    Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile 92
    PRO-02 - Drug Profile 93
    R-190 - Drug Profile 94
    Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 96
    Recombinant Protein for Age Related Macular Degeneration - Drug Profile 97
    Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 98
    Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 99
    Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 100
    Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 101
    Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 102
    Renaparin - Drug Profile 103
    Sanguinate - Drug Profile 104
    Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile 106
    Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 107
    Small Molecule to Inhibit HSP90 for Ischemia Reperfusion Injury - Drug Profile 108
    Small Molecules for Ischemia Reperfusion Injury - Drug Profile 109
    Small Molecules for Ischemia Reperfusion Injury - Drug Profile 110
    Small Molecules for Ischemia Reperfusion Injury - Drug Profile 111
    Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 112
    Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile 113
    Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile 114
    Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 115
    Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 116
    sodium nitrite - Drug Profile 117
    Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 118
    Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 119
    terameprocol - Drug Profile 120
    tiprelestat - Drug Profile 121
    TMS-007 - Drug Profile 125
    UCF-101 - Drug Profile 126
    UWA-TAT - Drug Profile 127
    Vanadis-03 - Drug Profile 128
    VCP-746 - Drug Profile 129
    YQ-23 - Drug Profile 130
    Ischemia Reperfusion Injury - Dormant Projects 131
    Ischemia Reperfusion Injury - Discontinued Products 134
    Ischemia Reperfusion Injury - Product Development Milestones 135
    Featured News & Press Releases 135
    Appendix 142
    Methodology 142
    Coverage 142
    Secondary Research 142
    Primary Research 142
    Expert Panel Validation 142
    Contact Us 142
    Disclaimer 143

    List of Tables

    Number of Products under Development for Ischemia Reperfusion Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
    Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corp (Inactive), H1 2017
    Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals LLC, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Hope Pharmaceuticals Inc, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Kowa Company Ltd, H1 2017
    Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Omeros Corp, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Orexo AB, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Proteo Inc, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2017
    Ischemia Reperfusion Injury - Pipeline by Recordati SpA, H1 2017
    Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Ischemia Reperfusion Injury - Dormant Projects, H1 2017
    Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Ischemia Reperfusion Injury - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Ischemia Reperfusion Injury, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amyndas Pharmaceuticals LLC
    Angion Biomedica Corp
    Biomedica Management Corp (Inactive)
    Bolder Biotechnology Inc
    Corline Biomedical AB
    Curatis Pharma GmbH
    Erimos Pharmaceuticals LLC
    Hope Pharmaceuticals Inc
    Ischemix Inc
    Kowa Company Ltd
    NovelMed Therapeutics Inc
    Omeros Corp
    Opsona Therapeutics Ltd
    Orexo AB
    Pharming Group NV
    Prolong Pharmaceuticals LLC
    Proteo Inc
    Prothix BV
    Recordati SpA
    SBI Pharmaceuticals Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ischemia-reperfusion-injury-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments